Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

Abstract

In Table 1 "Properties of currently available glucose-lowering agents that may guide treatment choice in individual patients with type 2 diabetes mellitus" vildagliptin was incorrectly assigned footnote "a" (Limited use in the U.S./Europe) instead of footnote "b" (Not licensed in the U.S.).The online version reflects these changes.